Literature DB >> 23578315

Fatigue among short- and long-term thyroid cancer survivors: results from the population-based PROFILES registry.

Olga Husson1, Willy-Anne Nieuwlaat, Wilma A Oranje, Harm R Haak, Lonneke V van de Poll-Franse, Floortje Mols.   

Abstract

BACKGROUND: The aims of this study were (i) to obtain insight into the prevalence of fatigue among short- and long-term thyroid cancer (TC) survivors, by comparing a sample of TC survivors with an age- and sex-matched normative population, and (ii) to investigate which demographic, clinical, and TC-specific health-related quality of life (HRQoL) characteristics were associated with fatigue.
METHODS: All patients found to have TC between 1990 and 2008, as registered in the Eindhoven Cancer Registry, received a cross-sectional survey on fatigue (Fatigue Assessment Scale), TC-specific HRQoL (THYCA-QoL), and psychological distress (Hospital Anxiety and Depression Scale). The fatigue scores were compared with those of an age- and sex-matched normative population (n=530). Multiple logistic regression analyses were conducted to investigate the independent associations between clinical and demographic characteristics, TC-specific HRQoL, and psychological distress with fatigue.
RESULTS: Eighty-six percent (n=306) responded. TC survivors were more often classified as fatigued or very fatigued (short-term <5 years: 43%; long-term 5-10 years: 44%; long-term 10-15 years: 47%; long-term >15 years: 39%) compared to the normative population (25%; p<0.001). Anxiety (odds ratio (OR) 1.15, 95% confidence interval [CI] 1.03-1.28) and depression (OR 1.43 [CI 1.22-1.68]) were associated with fatigue, as was also the case for TC-specific neuromuscular (OR 1.03 [CI 1.01-1.06]), concentration (OR 1.03 [CI 1.01-1.06]), and psychological TC-specific HRQoL (OR 1.06 [CI 1.02-1.10]).
CONCLUSION: Short- and long-term TC survivors report higher levels of fatigue than an age- and sex-matched normative population do. Both TC-specific HRQoL and psychological distress were associated with fatigue.

Entities:  

Mesh:

Year:  2013        PMID: 23578315      PMCID: PMC3783928          DOI: 10.1089/thy.2013.0015

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  44 in total

1.  Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale.

Authors:  Helen J Michielsen; Jolanda De Vries; Guus L Van Heck
Journal:  J Psychosom Res       Date:  2003-04       Impact factor: 3.006

Review 2.  Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.

Authors:  Geoffrey R Norman; Jeff A Sloan; Kathleen W Wyrwich
Journal:  Med Care       Date:  2003-05       Impact factor: 2.983

3.  Postoperative quality of life among patients with thyroid cancer.

Authors:  Sheng-Miauh Huang; Chen-Hsen Lee; Li-Yin Chien; Hsueh-Erh Liu; Chen-Jeng Tai
Journal:  J Adv Nurs       Date:  2004-09       Impact factor: 3.187

4.  Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  F Pacini; M G Castagna; L Brilli; G Pentheroudakis
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

Review 5.  Fatigue, endocrinopathies, and metabolic disorders.

Authors:  Gregory Kaltsas; Alexandros Vgontzas; George Chrousos
Journal:  PM R       Date:  2010-05       Impact factor: 2.298

Review 6.  I'm so tired: biological and genetic mechanisms of cancer-related fatigue.

Authors:  Andrea Barsevick; Marlene Frost; Aeilko Zwinderman; Per Hall; Michele Halyard
Journal:  Qual Life Res       Date:  2010-10-16       Impact factor: 4.147

7.  Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms.

Authors:  Charles S Cleeland; Gary J Bennett; Robert Dantzer; Patrick M Dougherty; Adrian J Dunn; Christina A Meyers; Andrew H Miller; Richard Payne; James M Reuben; Xin Shelley Wang; Bang-Ning Lee
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

8.  Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction.

Authors:  April Mendoza; Brian Shaffer; Daniel Karakla; M Elizabeth Mason; David Elkins; Thomas E Goffman
Journal:  Thyroid       Date:  2004-02       Impact factor: 6.568

9.  Descriptive epidemiology of thyroid cancer in France: incidence, mortality and survival.

Authors:  M Colonna; N Bossard; A-V Guizard; L Remontet; P Grosclaude
Journal:  Ann Endocrinol (Paris)       Date:  2009-12-29       Impact factor: 2.478

10.  Decreased health-related quality of life in disease-free survivors of differentiated thyroid cancer in Korea.

Authors:  Ji In Lee; Soo Hyun Kim; Alice H Tan; Hee Kyung Kim; Hye Won Jang; Kyu Yeon Hur; Jae Hyeon Kim; Kwang-Won Kim; Jae Hoon Chung; Sun Wook Kim
Journal:  Health Qual Life Outcomes       Date:  2010-09-15       Impact factor: 3.186

View more
  27 in total

1.  Variation in fatigue among 6011 (long-term) cancer survivors and a normative population: a study from the population-based PROFILES registry.

Authors:  Olga Husson; Floortje Mols; Lonneke van de Poll-Franse; Jolanda de Vries; Goof Schep; Melissa S Y Thong
Journal:  Support Care Cancer       Date:  2015-01-06       Impact factor: 3.603

2.  Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue.

Authors:  Diana M Norden; Raymond Devine; Sabahattin Bicer; Runfeng Jing; Peter J Reiser; Loren E Wold; Jonathan P Godbout; Donna O McCarthy
Journal:  Physiol Behav       Date:  2014-12-30

3.  A Qualitative Analysis of the Preoperative Needs of Patients With Papillary Thyroid Cancer.

Authors:  Susan C Pitt; Elizabeth Wendt; Megan C Saucke; Corrine I Voils; Jason Orne; Cameron L Macdonald; Nadine P Connor; Rebecca S Sippel
Journal:  J Surg Res       Date:  2019-07-12       Impact factor: 2.192

4.  Association of Preferences for Papillary Thyroid Cancer Treatment With Disease Terminology: A Discrete Choice Experiment.

Authors:  Brooke Nickel; Kirsten Howard; Juan P Brito; Alexandra Barratt; Ray Moynihan; Kirsten McCaffery
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-10-01       Impact factor: 6.223

5.  Ibuprofen ameliorates fatigue- and depressive-like behavior in tumor-bearing mice.

Authors:  Diana M Norden; Donna O McCarthy; Sabahattin Bicer; Raymond D Devine; Peter J Reiser; Jonathan P Godbout; Loren E Wold
Journal:  Life Sci       Date:  2015-10-20       Impact factor: 5.037

6.  Tumor growth increases neuroinflammation, fatigue and depressive-like behavior prior to alterations in muscle function.

Authors:  Diana M Norden; Sabahattin Bicer; Yvonne Clark; Runfeng Jing; Christopher J Henry; Loren E Wold; Peter J Reiser; Jonathan P Godbout; Donna O McCarthy
Journal:  Brain Behav Immun       Date:  2014-08-04       Impact factor: 7.217

7.  Energy level and fatigue after surgery for thyroid cancer: A population-based study of patient-reported outcomes.

Authors:  David T Hughes; David Reyes-Gastelum; Kevin J Kovatch; Ann S Hamilton; Kevin C Ward; Megan R Haymart
Journal:  Surgery       Date:  2019-09-30       Impact factor: 3.982

8.  Effect of a Change in Papillary Thyroid Cancer Terminology on Anxiety Levels and Treatment Preferences: A Randomized Crossover Trial.

Authors:  Brooke Nickel; Alexandra Barratt; Kevin McGeechan; Juan P Brito; Ray Moynihan; Kirsten Howard; Kirsten McCaffery
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-10-01       Impact factor: 6.223

9.  Health-Related Quality of Life in Asian Differentiated Thyroid Cancer Survivors.

Authors:  Wing-Lok Chan; Horace Cheuk-Wai Choi; Brian Lang; Kai-Pun Wong; Kwok-Keung Yuen; Ka-On Lam; Victor Ho-Fun Lee; Dora Kwong
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

10.  Patients' Reaction to Diagnosis with Thyroid Cancer or an Indeterminate Thyroid Nodule.

Authors:  Susan C Pitt; Megan C Saucke; Elizabeth M Wendt; David F Schneider; Jason Orne; Cameron L Macdonald; Nadine P Connor; Rebecca S Sippel
Journal:  Thyroid       Date:  2020-11-04       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.